肉毒杆菌毒素治疗帕金森病相关下肢肌张力障碍。8 年回顾性研究

IF 1.9 Q3 CLINICAL NEUROLOGY Clinical Parkinsonism Related Disorders Pub Date : 2024-01-01 DOI:10.1016/j.prdoa.2024.100260

Antonia Schonwald , Katherine Amodeo , Victoria Levy , Fabio Danisi

{"title":"肉毒杆菌毒素治疗帕金森病相关下肢肌张力障碍。8 年回顾性研究","authors":"Antonia Schonwald , Katherine Amodeo , Victoria Levy , Fabio Danisi","doi":"10.1016/j.prdoa.2024.100260","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.</p><p>Cases</p><p>14 patients with LED received an average of 3.86 injections (1–8). Mean interval was 40 weeks (median of 25). Average dose was 182 units. Injections were well-tolerated. Using a 6 point scale, there was an average of 3.37 point improvement in disability after each session, with average duration of 28.56 weeks (median 11 weeks). After mean follow-up of 101 weeks, disabling dystonia was not present in 11 of 14 patients.</p></div><div><h3>Conclusions</h3><p>Botulinum toxin is safe and effective in PD related LED. Good response to the first two injection sessions was significantly associated with greater likelihood of long-term response. Assertive BoNTA dosing may lead to sustained remission of symptoms. As natural history of LED in PD has not been reported, prospective placebo-controlled studies are needed.</p></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"11 ","pages":"Article 100260"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590112524000318/pdfft?md5=6048d78b1cb0a01adf92551e36356c7e&pid=1-s2.0-S2590112524000318-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Botulinum toxin therapy in Parkinson disease-related lower limb dystonia. An 8 year retrospective review\",\"authors\":\"Antonia Schonwald , Katherine Amodeo , Victoria Levy , Fabio Danisi\",\"doi\":\"10.1016/j.prdoa.2024.100260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.</p><p>Cases</p><p>14 patients with LED received an average of 3.86 injections (1–8). Mean interval was 40 weeks (median of 25). Average dose was 182 units. Injections were well-tolerated. Using a 6 point scale, there was an average of 3.37 point improvement in disability after each session, with average duration of 28.56 weeks (median 11 weeks). After mean follow-up of 101 weeks, disabling dystonia was not present in 11 of 14 patients.</p></div><div><h3>Conclusions</h3><p>Botulinum toxin is safe and effective in PD related LED. Good response to the first two injection sessions was significantly associated with greater likelihood of long-term response. Assertive BoNTA dosing may lead to sustained remission of symptoms. As natural history of LED in PD has not been reported, prospective placebo-controlled studies are needed.</p></div>\",\"PeriodicalId\":33691,\"journal\":{\"name\":\"Clinical Parkinsonism Related Disorders\",\"volume\":\"11 \",\"pages\":\"Article 100260\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590112524000318/pdfft?md5=6048d78b1cb0a01adf92551e36356c7e&pid=1-s2.0-S2590112524000318-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Parkinsonism Related Disorders\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590112524000318\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Parkinsonism Related Disorders","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590112524000318","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景下肢肌张力障碍（LED）是帕金森病（PD）的一种常见并发症。病例14名下肢肌张力障碍患者平均接受了3.86次注射（1-8次）。平均间隔时间为 40 周（中位数为 25 周）。平均剂量为 182 单位。注射耐受性良好。采用 6 点评分法，每次治疗后残疾状况平均改善 3.37 点，平均持续时间为 28.56 周（中位数为 11 周）。平均随访101周后，14名患者中有11名不再出现致残性肌张力障碍。对前两次注射的良好反应与长期反应的可能性显著相关。坚持注射BoNTA可使症状持续缓解。由于尚未报道帕金森病LED的自然病史，因此需要进行前瞻性安慰剂对照研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Botulinum toxin therapy in Parkinson disease-related lower limb dystonia. An 8 year retrospective review

Background

Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.

Cases

14 patients with LED received an average of 3.86 injections (1–8). Mean interval was 40 weeks (median of 25). Average dose was 182 units. Injections were well-tolerated. Using a 6 point scale, there was an average of 3.37 point improvement in disability after each session, with average duration of 28.56 weeks (median 11 weeks). After mean follow-up of 101 weeks, disabling dystonia was not present in 11 of 14 patients.

Conclusions

Botulinum toxin is safe and effective in PD related LED. Good response to the first two injection sessions was significantly associated with greater likelihood of long-term response. Assertive BoNTA dosing may lead to sustained remission of symptoms. As natural history of LED in PD has not been reported, prospective placebo-controlled studies are needed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊